Navigation Links
Patients with cancer who stop hospice care boost health-care costs
Date:9/23/2010

Researchers at Mount Sinai School of Medicine have found that the costs of care for patients with cancer who disenrolled from hospice were nearly five times higher than for patients who remained with hospice. Patients who disenroll from hospice are far more likely to use emergency department care and be hospitalized. The results are published in the October 1 issue of the Journal of Clinical Oncology.

Led by Melissa D.A. Carlson, PhD, Assistant Professor of Geriatrics and Palliative Medicine, and Elizabeth H. Bradley, PhD, Professor of Public Health at Yale University, the research team evaluated data from 90,826 patients with cancer served by 1,384 hospices in the Surveillance, Epidemiology and End Results (SEER)-Medicare database between 1998 and 2002. Nearly 11 percent of these patients disenrolled from hospice care and had significantly higher health care use and costs than those who remained in hospice until death.

"Our data suggest that oncologists should be aware of the dramatic financial and physical toll that disenrolling from hospice can have on a patient with cancer," said Dr. Carlson. According to Dr. Bradley, "We do not really understand why some patients disenroll from hospice, especially as many had conditions that typically fit hospice care. The number was higher than we expected and would be good to investigate further." The paper recommends that oncologists should connect with palliative care teams where available and try to ensure that the patient and family are supported following hospice disenrollment."

The researchers found that 33.9 percent of the patients who had disenrolled from hospice care were admitted to an emergency department, while only 3.1 percent of those who remained in hospice care until death were. Additionally, 39.8 percent of disenrolled patients were admitted to the hospital as an inpatient where only 1.6 percent of enrolled patients were. Disenrolled patients also spent an average of 19.3 days in the hospital, whereas enrolled patients spent an average of 6.7 days.

The Medicare expenditures that the researchers evaluated included hospice care, hospitalizations, physician visits, outpatient care, medical equipment and supplies, and home health care services. Patients who stayed with hospice incurred $6,537 in expenses from the time of hospice enrollment to death, while those who did not incurred $30,848 in expenses.

The study did not investigate why patients disenrolled from hospice care and does not include individuals who were enrolled in a Medicare managed care organization before hospice enrollment. The researchers recommend that future studies include patient and caregiver interviews to help understand the hospice disenrollment process.

"Currently, 39 percent of decedents in this country were under the care of a hospice," continued Dr. Carlson. "Rather than focusing on how to decrease Medicare expenditures by restricting access to the Medicare Hospice Benefit, policy makers should focus on how to decrease the potential barriers to remaining enrolled with hospice until death, with an eye to both decreasing Medicare costs and potentially improving patient and family outcomes."


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Counseling May Not Help Heart Failure Patients Comply With Rx
2. Intensive care diaries protect patients from PTSD
3. JAK inhibitor provides rapid, durable relief for myelofibrosis patients
4. Anemia Drugs Could Pose Threat to Some Kidney Patients
5. Death at home less distressing for cancer patients and families
6. What can health-care facilities do to help patients better understand medical information
7. Dying at Home Often Easier on Cancer Patients, Caregivers
8. New task force report on bisphosphonate use and atypical femur fractures in osteoporosis patients
9. Breakthrough in drug trial offers hope for heart attack patients
10. Brain stimulation can help partially paralyzed stroke patients regain use of their muscles
11. Stenting Riskier for Older Patients With Blocked Carotid Artery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... Conference from Sept. 18 to 20. , The two-day conference is focused on ... the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. The ...
(Date:6/23/2017)... ... , ... Ross Insurance Agency ( http://www.rossinsuranceagency.com ) saves clients ... (FEMA) recent update of flood zones, more people than ever are in flood ... to reflect the actual risk in flood zone areas during a time when ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance Services, ... communities in the greater Chicago metropolitan area, is embarking on a charity drive ... in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of the ...
(Date:6/22/2017)... FL (PRWEB) , ... June 22, 2017 , ... Branches, ... received more than $245,000 in grant funding to support its programs focused on providing ... Branches, Inc. was awarded a grant by the Foundation of $15,000 to support its ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National Health System ... (AHA) to launch a Rheumatic Heart Disease Center, with the goal of developing ... heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities across the ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that the U.S. Food and Drug Administration ... June 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning ... manufacturing facility is a measure of the progress we ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
Breaking Medicine Technology: